ILAE Neurobiology symposium: The tales of tau in epilepsy: on treatments, biomarkers and translation
Co-chairs: Aristea Galanopoulou (USA) & David Henshall (Ireland)

• Targeting tau in epilepsy: lessons from animal models - Sandy Schultz (USA)
• Tau as a biomarker of epilepsy: the EpiBioS4Rx experience - Patricia Saletti (USA)
• Tau pathologies: understanding and targeting their complexities - Hilal A. Lashuel (Switzerland)
• Targeting tau in human epilepsy: why, when, how? - Matthias Koepp (United Kingdom)

Tau protein is a microtubule associated protein that has been receiving increasing level of attention not only for its potential role in neurodegenerative disorders but also for its role in epilepsy and associated comorbidities. Evidence of abnormal tau pathology has been found in humans with epilepsy as well as animal models of epilepsies. Various etiologies of adult or pediatric epilepsies (e.g., due to traumatic brain injury, focal cortical dysplasias and cortical malformations, temporal lobe epilepsy, epileptic encephalopathies) have been linked with tau pathologies, such as hyperphosphorylated tau. Experimental treatments targeting these tau pathologies have been tested in animal models providing valuable insight into relevance of abnormal tau deposits for epilepsy and its comorbidities or consequences. Research into tau-relevant biomarkers (imaging, CSF and blood), both in animals and humans, has also provided insights into opportunities and challenges for the monitoring of disease development and progression in hopes of providing a tool to stop progression.

This symposium will therefore summarize the current state of progress on tau-related research that pertains to key aspects of epilepsies. The session will be chaired by Drs Henshall and Galanopoulou. After a brief introduction of the session by the chairs, Dr Sandy Shultz (Australia) will discuss the preclinical studies that introduced hyperphosphorylated tau in the pathogenesis of epilepsy. Dr Patricia Saletti (USA, junior investigator) will present data from the EpiBioS4Rx multicenter preclinical study on post-traumatic epilepsy on the role of  hyperphosphorylated tau as a therapy target and biomarker of traumatic brain injury and epilepsy. Dr Hilal Lashuel (Switzerland) will elaborate on the structural / functional complexities of tau pathologies and significance for disease progression, spreading across cells and treatment strategies. Dr Matthias Koepp (UK) will finally bring this into a clinical perspective discussing the clinical evidence on why and when tau pathologies may be relevant for human epilepsies, the progress into biomarker use for early detection and monitoring of progression and implications for the design of clinical studies targeting tau for epilepsy and its comorbidities. The discussion will address issues on translation from the preclinical to clinical arena.

The topic addresses important neurobiological aspects of tau research that pertain to clinicians or professionals involved in the care of individuals with epilepsy or comorbidities, as well as to basic / translational scientists. The learning objectives are to:

• update on the preclinical progress on the role of tau in epilepsy and the potential of tau-targeting approaches for disease modifying and antiepileptogenic treatments,
• update on the role of tau as a biomarker of traumatic brain injury and epilepsy
• learn the mechanisms of tau pathologies and relevance for disease progression in epilepsy
• learn of progress in clinical research on the relevance of tau for human epilepsies and use of in vivo biomarkers for tau pathologies, and implications for testing new therapies for epilepsy.

ILAE- Europe/EAN symposium: Neurology meets epileptology: Hot Topics 2022
Co-chairs: Philippe Ryvlin (Switzerland) & Barbara Tettenborn (Switzerland)

• Driving and epilepsy – regulations and guidelines in Europe: Uniform or unwordly? Rune Markhus (Norway)
• Implications of SANAD II for our practical strategies? Barbara Tettenborn (Switzerland)
• COVID19 and epilepsy – Bernhard Steinhoff (Germany)
• Status epilepticus: Update 2022 – Markus Leitinger (Austria)
• Pregnancy, folic acid and antiseizure medications – an update - Marte-Helene Bjork (Norway)

Half-day Surgery Symposium

Co-chairs: Karl Schaller (Switzerland) & Karl Röessler (Austria)

• How to avoid complications in SEEG. Jorge Gonzalez Martinez (USA)
• A multimodal brain atlas for combined intracranial electrode monitoring in patients with medically intractable epilepsy - Dennis Spencer  (USA)
• Current neuronavigation tools in epilepsy surgery - Christian Dorfer  (Austria)
• Neurosurgeon's role in gene therapy for epilepsy - Dan Curry  (USA)
• Neuromodulation options in patients with temporal lobe epilepsy- Arthur Cukiert  (Brazil)
• Insular epilepsy surgery - Alexander Weil  (Canada)
• How to approach surgical patients with failures – a neurologists perspective? – Susanne Knake (Germany)

Epilepsy in emergencies

 Co-chairs: J. Helen Cross (United Kingdom) & Ali Asadi-Pooya (Iran)

• Epilepsy care during COVID-19 Pandemic - Maria Mazurkiewicz-Bełdzińska (Poland) 
• Epilepsy Care during natural disasters  - Julie Hall (United Kingdom)
• Epilepsy Care during conflicts  - J. Helen Cross (United Kingdom)

Rare and Complex Epilepsies in 2030 and the role of ERN EpiCARE
Chair: Alexis Arzimanoglou (France)

• Epilepsy Care in Europe: learning from the experience of the European Reference Network EpiCARE - Alexis Arzimanoglou (France)
• Optimal interaction between the ERN EpiCARE and national reference networks - Reetta Kalviainen (Finland)
• Evidence based Guidelines for rare and complex epilepsies – Challenges in development, dissemination, education, and training - Masa Malenica (Croatia)
• A registry for rare and complex epilepsies and the challenges of data sharing – Lieven Lagae (Belgium)
• EU grants, epilepsy research and ERN EpiCARE – Helen Cross (United Kingdom)
• ERN EpiCARE and Patient Advocacy Groups - Isabella Brambilla (Italy)

Psychiatric Comorbidities in Persons with Epilepsy: Update on Guidelines and Recommendations
Chair: Kette Valente (Brazil)

• My child's behavior has been a problem lately. Is it safe to prescribe metilphenidate considering his diagnosis of Dravet syndrome?” 
• Guidelines on treatment of ADHD in pediatric epilepsy - Stéphane Auvin (France)
  Despite the fact that my child's seizures are controlled, she has been sad lately. What can we do about it?" Recommendations on diagnosis and treatment of Depression for Children with Epilepsy - Kette Valente (Brazil)
• My child's events are not the same after epilepsy surgery. It seems that they are associated mainly with stress. Is it possible?
  PNES in children: Recommendations about assessment and management – Colin Reilly (United Kingdom)
• My doctor recommended me to take antidepressants but he is not sure. Is it safe for me to take antidepressants if I have epilepsy? What side effects could I get?
  Recommendations to pharmacological treatment of depression in persons with epilepsy – Marco Mula (United Kingdom)

Minimally Invasive Epilepsy Surgery
Chair: Vicente Villanueva (Spain)

• Laser interstitial thermotherapy (LiTT) in epilepsy surgery – Rodrigo Rocamora (Spain)
• SEEG-guided radiofrequency coagulation (SEEG-guided RF-TC) – Edouard Hirsch (France)
• Lesion guided radiofrequency thermocoagulation (L-RFTC) – Tim Wehner (Germany)
• When minimally invasive techniques are not indicated – Mar Carreňo (Spain)

Systematic reviews and meta-analyses in epilepsy: an interactive workshop on how to interpret and use them in clinical practice
Chair: Francesco Brigo (Italy)

• How and why to develop a systematic review – Simona Lattanzi (Italy)
• How to read and interpret systematic reviews and meta-analyses of interventional studies - Francesco Brigo (Italy)
• How to use systematic reviews and meta-analyses to inform clinical practice and public health policies – Anthony Marson (United Kingdom)

Real-time processing of brain biosignals; applied to epileptiform discharges, behavior, and cognition
Chair: Heinz Krestel (Switzerland)

• State of the art of machine learning algorithms for real-time biosignal processing, advantages, disadvantages, potential applications – Diyuan Lu (Germany)
• Brain-computer interfaces and its latencies – Heinz Krestel (Switzerland)
• Detection of transient cognitive impairment in dementia evaluation – Justina Rackauskaite (Switzerland)
• Detection of transient cognitive impairment in fitness-to-drive evaluation - Heinz Krestel (Switzerland)

Climate change and epilepsy: what to know and what to do?
Chair: Sanjay Sisodiya (United Kingdom)

• Climate change: personal experience – Galia Wilson (United Kingdom)
• What can we do? The experience of epilepsy climate change – Simona Balestrini (Italy)

Evolution of trial designs to improve treatment availability for infants: a regulatory opportunity/challenge
Chair: Stéphane Auvin (France)

• Overview of previous ASM trials in infants – Dennis Dlugos (USA)
• History of extrapolation of efficacy of ASM from adults to pediatrics – Jacqueline French (USA)
• Epidemiology and clinical characteristics of infantile epilepsies – Helen Cross (United Kingdom)
• Future designs for ASM trials in infants - Stéphane Auvin (France)

Personalising antiseizure treatment
Chair: Jan Novy (Switzerland)

• Predicting treatment efficacy – Chantal Depondt (Belgium)
• Therapeutic drug monitoring – Jan Novy (Switzerland)
• Inflammatory biomarkers – Annamaria Vezzani (Italy)
• Treatment emergent adverse events – Norman Delanty (Ireland)

Epilepsy Nursing: Local to Global Connections
Co-chairs: Karen Legg (Canada) and Sandra Dewar (USA)

• Nursing and the ILAE – Marielle Prevos-Morgant (Switzerland) and Samuel Wiebe (Canada)
• Current ILAE nursing section initiatives: Needs Assessment – Jane von Gaudecker (USA) and Patty Osborne-Shafer (USA)
• Nursing roles In epilepsy care – Tolu Olaniyan (United Kingdom), Sandra Dewar (USA), Karen Legg (Canada)
• Open group discussion: comments, questions, challenges in epilepsy nursing, epilepsy nursing needs - Karen Legg (Canada)

From cell to biomarker – renaissance of EEG?
Chairs: Caroline Neuray (Austria)  & Christos Lisgaras (USA)

• We did it! Demonstrating the path from cell to scalp - Christos Lisgaras (USA)
• But are we there yet? Current evidence for use of EEG-derived features as biomarkers – Tommaso Fedele (Germany)
• Stay calm! Limitations of EEG-use as biomarkers – Julia Jacobs-LeVan (Canada)

Reproductive hormones and epilepsy
Chair: Bruna Nucera (Italy)

• The influence of the ovaric cycle on seizure occurrence: focus on catamenial epilepsy - Bruna Nucera (Italy)
• Reproductive health in people with epilepsy: fertility and infertility – Ewa Czapinska-Ciepiela (Poland)
• Changes in seizure frequency and antiseizure therapy during pregnancy and breastfeeding – Barbara Mostacci (Italy)
• Sex differences in characteristics of idiopathic generalized epilepsies – Ali Asadi-Pooya (Iran)

EEC Forum: Epilepsy and employment -  limitations and solutions
Chair: Markus Leitinger (Austria)

• Epilepsy and employment: the many influencing factors and perspectives – Beata Majkowska-Zwolińska (Poland)
• Epilepsy surgery and employment – social and psychological similarities? – Mirja Steinbrenner (Germany)
• The stratification of workplaces and the information compartment model - Markus Leitinger (Austria)

EEC Forum: SUDEP - an uncomfortable but necessary discussion
Co-chairs: Adam Strzelczyk (Germany) & Luis Miguel Aras (Spain)

• Introduction and Welcome - Luis Miguel Aras (Spain)
• SUDEP, sleep and monitoring: Cohort study of Dravet patients and caregivers from Germany - Adam Strzelczyk (Germany)
• Recent update on SUDEP research and prevention – Phillippe Ryvlin (Switzerland)
• How to talk with families about SUDEP - TBC
• Round table and final discussion

ILAE- YES Brainstorming Sessions: Pitfalls in clinical trials and how to avoid them

Pitfalls in clinical trials and how to avoid them – Jacqueline French (USA)

ILAE- YES Brainstorming Sessions: How epilepsy papers are reviewed?

How epilepsy papers are reviewed? – Julia Jacobs Le Van (Canada)

ILAE- YES Brainstorming Sessions: How and when animal models are useful in epilepsy research

How and when animal models are useful in epilepsy research – Marco de Curtis (Italy)

Symposium of Excellence in Epileptology  

Co-chairs: Eugen Trinka (Austria) & Matthew Walker (United Kingdom)     

• Discovery and development of new antiepileptic drugs; what did I learnt from unsuccessful attempts - Meir Bialer (Israel)   
• Capturing brain impairment in the early stages of human epilepsy – Simon Keller (United Kingdom)  

• Advanced neurophysiology for epilepsy surgery - Maeike Zijlmans (Netherlands)  

Award Symposium: Epilepsia Prize 2022 - Basic Science  

Co-chairs: Astrid Nehlig (France) & Michael Sperling (USA)  

• First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat’ – Carmen de Caro (Italy)   

Award Symposium: Epilepsia Open Prize 2022 – Clinical  

Chair: Aristea Galanopoulou (USA)    

• The epileptogenic zone in children with tuberous sclerosis complex is characterized by prominent features of focal cortical dysplasia – Hanna Hulshof (Netherlands) & Barbara Benova (Czech Republic)   

Award Symposium: Epilepsia Prize 2022 – Clinical  

Co-chairs: Astrid Nehlig (France) & Michael Sperling (USA)    

• Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs – Margherita Contento (Italy)   

Award Symposium: Epileptic Disorders Prize 2022  

Chair: Sándor Beniczky (Denmark)    

• Transient infant movements (TIM): frequent infant non-pathological developmental motor phenomena - Ludovica Maria Piscitello (Italy)  

View Patient Forum programme

Adult Epileptology 1

Co-chairs: Mar Carreňo (Spain) & Stanislav Groppa (Moldova)

• A library of quantitative markers of seizure severity: distinguishing between seizure types and detecting circadian modulation. - Sarah Jane Gascoigne (United Kingdom)
• Prognosis of structural acute symptomatic seizures – a prospective observational study - Bernd Vorderwülbecke (Germany)
• “Benign” EEG for prognostication of favorable outcome after cardiac arrest: a reappraisal - Helene Fenter (Switzerland)
• Seizure detection using subcutaneous ECG during video-EEG-monitoring and home monitoring; a prospective, proof-of-concept study. - Jesper Jeppesen (Denmark)
• Reduced REM sleep: a potential biomarker for diagnosing epilepsy at epilepsy monitoring units - Stefan Wolking (Germany)
• Exploratory study of blood biomarkers in patients with post-stroke epilepsy - Laura Abraira (Spain)

Basic Science

Co-chairs: Marco de Curtis (Italy) Manisha Patel (USA)

• Understanding the gene expression diurnal rhythmicity in experimental epileptogenesis - Cristina Reschke (Ireland)
• Role of myeloid differentiation response 88 protein in seizures and cognition in autoimmune encephalitis - Olga Taraschenko (United States)
• Hippocampal area CA2 as a novel therapeutic target in epilepsy - Christos Panagiotis Lisgaras (United States)
• Investigation of second hit hypothesis in DEPDC5 and TSC double mutant zebrafish: a phenotypic and transcriptomic analysis - Ann-Sofie De Meulemeester (Belgium)
• Closed-loop control of neuronal network excitability using adenosine photopharmacology - Robrecht Raedt (Belgium)
• Reflections of very high-frequency oscillations (>500Hz) in routine stereo-EEG - Zuzana Vašíčková (Czech Republic)

Drug Therapy 1

Co-chairs: Sanaz Ahmadi Karvigh (Iran) & Rafal Kaminiski (Italy)

• A cohort study of pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency - Allan Bayat (Denmark)
• Long-Term Perampanel Monotherapy and Health-Related Quality of Life in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures: FREEDOM Study 342 Extension Phase – Leock Y Ngo (Korea, Republic of)
• Safety, Pharmacokinetics (PK), and Cerebrospinal (CSF) Exposure Data from the Ongoing Phase 1/2a MONARCH Study of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) - Linda Laux (United States)
• Psychological assessment prior to and after switch from levetiracetam to brivaracetam: a controlled questionnaire study - Bernhard Steinhoff (Germany)
• Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalised-Onset Seizures - Taoufik Alsaadi (United Arab Emirates)
• Perampanel for the Treatment of Patients with Idiopathic Generalised Epilepsy in Clinical Practice - Fabio Rossini (Austria)

Paediatric Epileptology 1

Co-chairs: Masa Malenica (Croatia) & Susanne Schubert -Bast (Germany)

• How is (Mesial) frontal lobe seizure semiology characterised in post-surgical seizure-free paediatric patients? A retrospective analysis at Great Ormond Street Hospital, London. - Thijs van Dalen (United Kingdom)
• Imaging the cytoarchitectural changes within focal cortical dysplasiausing diffusion tensor imaging - Antonio Giulio Gennari (Switzerland)
• A neverending challenge: epilepsy secondary to MECP2 mutation - Elena González Alguacil (Spain)
• The ENVISION study, an international, prospective natural history study in young children with scn1a+ dravet syndrome – Sameer Zuberi (United Kingdom)
• Donepezil as precision therapy for gain-of-function variants in kcnq2/kcnq3 encephalopathy - Andreea Nissenkorn (Israel)
• Neonatal seizures: use of the last ILAE Classification in a retrospective observational cohort study. - Benedetta Martinucci (Italy)

Clinical Neurophysiology 1

Co-chairs: Caroline Neurary (Austra)

• Open Access EEG Data Via DICOM Standard - Clemens Lang (Austria)
• Detecting Interictal Discharges in Ultra Long-term Subcutaneous Electroencephalography - Asbjoern W. Helge (Denmark)
• Brain networks functional connectivity changes after stereotactic thermocoagulation in drug-resistant epilepsy patients - Sara F. Simula (France)
• A Retrospective Study of the Correlation Between Duration of Monitoring in Epilepsy Monitoring Unit and Diagnostic Yield. - Mohammad Hijaz Adenan (Ireland)
• Refining epileptogenic high-frequency oscillations using deep learning: a reverse engineering approach - Hiroki Nariai (United States)
• Is ultra long-term subcutaneous EEG a game changer in future management of epilepsy? - Jonas Duun-Henriksen (Denmark)
•  

Epilepsy Surgery

Co-chairs: Hermann Stefan (Germany) & Ido Strauss (Israel)

• Tailored epilepsy surgery with high frequency oscillations versus spikes in intra-operative electrocorticography; results of the RCT HFO trial - Maryse van 't Klooster (Netherlands)
• Online Calculator for Seizure Freedom Following Pediatric Hemispherectomy: A post hoc analysis of the HOPS study - Evan Dimentberg (Canada)
• Effects of anterior temporal lobe resection on cortical morphology - Karoline Leiberg (United Kingdom)
• Why patients with drug resistant focal epilepsy decline further diagnostics and resections following presurgical assessment – a prospective study - Mirja Steinbrenner (Germany)
• Seizure outcome prediction after pediatric epilepsy surgery:a Brain machine learning approach - Chiara Pepi (Italy)
• Epilepsy surgery in the first six months of life: A systematic review and meta-analysis - Konstantin L. Makridis (Germany)

Adult Epileptology 2

Co-chairs: Philippe Gelisse (France) & Kristina Malmgren (Sweden)

• Ictal semiology of epileptic seizures with insular and temporal genesis - Eva Martinez-Lizana (Germany)
• Is drug resistant temporal lobe epilepsy in fact a neurodegenerative disorder? - Eva Zatloukalova (Czech Republic)
• Risk of epilepsy after a single unprovoked seizure in individuals after traumatic brain injury - Markus Karlander (Sweden)
• Determinants of Medication adherence in people with Epilepsy: a multicentric, cross-sectional and observational study - Flavia Narducci (Italy)
• Epilepsy and Multiple Sclerosis:clinical, radiological, electrophysiological and neuropsychological aspects - Giacomo Evangelista (Italy)
• Sleep architecture, interictal epieptiform discharges and sleep co-morbidities in patientswith progressive myoclonus epilepsy type 1 (EPM1) - Jelena Hyppönen (Finland)

Drug Therapy 2

Co-chairs: Dana Ekstein (Israel) & Bruna Nucera (Italy)

• D-galactose supplementation for the treatment of patients with mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE): an interim analysis of a proof-of-concept trial - Angel Aledo-Serrano (Spain)
• Perampanel in rare genetic epilepsies- is there a targeted effect? - Angelo Russo (Italy)
• Treatment of Status Epilepticus in Poststroke Epilepsy with Last Generation Anti-Seizure Medication - Yaroslav Winter (Germany)
• Effect of Add-on Cannabidiol on Seizure Frequency and Seizure-Free Intervals in Patients With Seizures Associated With Tuberous Sclerosis Complex: Phase 3 Trial GWPCARE6 Post-Hoc Analysis - Farhad Sahebkar (United States)
• Long-Term Efficacy and Safety of Perampanel Monotherapy in Patients with Newly Diagnosed/Currently Untreated Recurrent Focal-Onset Seizures: FREEDOM Study 342 Extension Phase - Takamichi Yamamoto (Japan)
• Stiripentol efficacy and tolerability for drug-resistant epilepsy treatment in tuberous sclerosis complex - Gewalin Aungaroon (United States)

Paediatric Epileptology 2

Co-chairs: Bosa Jocic-Jakubi (Serbia) & Gudrun Gröppel (Austria)

• Post-stroke epilepsy in children is rare and often not stroke-related: data from the Swiss Neuropediatric Stroke Registry - Andrea Rüegger (Switzerland)
• Seizures and epilepsy in patients with Neonatal Arterial Ischemic Stroke: preliminary results from the Italian Registry of Infantile Thrombosis - Marta Conti (Italy)
• Development of seizures in children undergoing stem cell transplantation - Eulàlia Turón-Viñas (Spain)
• Valproate-associated cerebral atrophy in children with epilepsy - Johanna Umlauf (Germany)
• Gain-of-function SCN1A variants cause spectrum of early onset epileptic encephalopathies that respond to sodium channel blocking therapies - Andreas Brunklaus (United Kingdom)
• Old drugs, new indications: efficacy of amantadine for refractory absences and electrical status epilepticus in sleep in children - Victor Soto Insuga (Spain)

Neuroimaging

Co-chairs: Andrea Bernasconi (Canada) & Giorgi Kuchukhidze (Austria)

• Altered correlation of simultaneously recorded EEG-fMRI connectomes in temporal lobe epilepsy - Jonathan Wirsich (Switzerland)
• MELD project: MRI automated detection and atlasing of lesions in focal cortical dysplasia - Konrad Wagstyl (Germany)
• Focal “scalp-invisible” epileptic activity is associated with increased large-scale brain network efficiency - Nicolas Roehri (Switzerland)
• 7T metabolic MRI in focal epilepsy - Sarah M Jacobs (Netherlands)
• Emotion perception and recognition in juvenile myoclonic epilepsy - Lucas Johannes Rainer (Austria)
• Disorganization of language and working memory systems in frontal versus temporal lobe epilepsy - Lorenzo Caciagli (United Kingdom)

Adult Epileptology 3

Co-chairs: Silvia Bozzetti (Italy) & Manjari Tripathi (India)

• Pharmacological treatment influences multidien cycles in focal epilepsy - Cecilia Friedrichs-Maeder (Switzerland)
• Awareness alteration in focal epilepsy is related to loss of signal complexity and information processing - NADA EL YOUSSEF (France)
• Efficacy of perampanel in nocturnal seizures in adult patients with epilepsy - Samuel López Maza (Spain)
• Cavum Septum Pellucidum on MRI is a marker of generalised convulsive epilepsy. - Emma Dolan (Ireland)
• Psychiatric and cognitive adverse events of eslicarbazepine acetate (ESL) monotherapy on adults with focal seizures: Results from a randomized, double-blind, active-controlled study and a 2-year open-label extension study. - Sophie Dupont (France)
• Duration of postictal impaired awareness after bilateral tonic-clonic seizures: EEG and patient characteristics - Masud Seyal (United States)

Clinical Neurophysiology 2

Co-chairs: Julia Jacobs (Germany) & Christos Lisgaras (USA)

• Patient-specific seizure forecasting using minimally-invasive subcutaneous EEG - a multicenter cohort analysis - Pedro F. Viana (United Kingdom)
• Quantitative analysis of EEG frequency composition in STXBP1developmental epileptic encephalopathy - Alberto Cossu (Denmark)
• Epileptic Spasms are associated with increased SEEG derived functional connectivity in tuberous sclerosis complex – Sylvain Rheims (France)
• Generalised epileptic fast activity is a biomarker for changes in seizure frequency in Lennox-Gastaut syndrome - Linda Dalic (Australia)
• ENCEVIS Automatic Seizure Detection - Evaluation in the setting of Epilepsy Monitoring Unit - Aleksandre Tsereteli (Georgia)
• What is the optimal duration of home-video-EEG monitoring for patients with less than daily seizures? A practical simulation study - Dana Ekstein (Israel)

Status Epilepticus

Co-chairs: Asel Jusupova (Kyrgyzstan) & Giada Giovannini (Italy)

• Spectrum of peri-ictal MRI abnormalities in status epilepticus - Giorgi Kuchukhidze (Austria)
• Peri-ictal MRI abnormalities in status epilepticus: Is there an optimal time window for an acute MRI? - Lukas Machegger (Austria)
• Machine-learning validation of the Epidemiology-based Mortality score in Status Epilepticus (EMSE) - Francesco Brigo (Italy)
• External validation of the Status Epilepticus Severity Score (STESS) to predict mortality: a machine-learning analysis - Simona Lattanzi (Italy)
• EEG seizures onset patterns and duration in focal status epilepticus - Giulia Turchi (Italy)
• Etiology of status epilepticus and its relation with peri-ictal MRI abnormalities - Pilar Bosque Varela (Austria)

Epidemiology

Co-chairs: Claudia Granbichler (Austria) & Francesca Sofia (Italy)

• The influence of comorbidity on mortality in patients with epilepsy and psychogenic non-epileptic seizures ​ - Wendyl D'Souza (Australia)
• Adherence patterns in antiseizure medications influencing the risk of Sudden Unexplained Death in Epilepsy: a data linkage study using dispensed prescriptions - Wendyl D'Souza (Australia)
• Risk factors for nodding syndrome and other forms of epilepsy in northern Uganda: a case-control study - Nolbert Gumisiriza (Uganda)
• Sudden unexpected death in epilepsy (SUDEP) in persons younger than 50 years – a retrospective nationwide cohort study in Denmark - Marius Kløvgaard (Denmark)
• Does Etiology Influence the Risk of Relapse After First Seizure? -
• The COVID-19 Pfizer BioNTech mRNA Vaccine and the Frequency of Seizures - Lilach Goldstein (Israel)

Neurostimulation

Co-chairs: Rodrigo Rocamora (Spain) & Silvia Bonelli (Austria)

• Characterization of neural dynamics between the anterior thalamus and the cortex in epilepsy patients - Giovanna Aiello (Switzerland)
• Role of Vagal Nerve Stimulation (VNS) on thalamo-cortical network: a study of somatosensory evoked potentials (SEPs) and quantitative electroencefalography (qEEG) - Giovanni Assenza (Italy)
• Personalized predictive modeling of epileptic network dynamics - Tena Dubcek (Switzerland)
• Laryngeal Motor Evoked Potentials as biomarkers of Vagus Nerve Stimulation responsiveness in drug-resistant epilepsy – Riem El Tahry (Belgium)
• DBS of thalamic centromedian nucleus for Lennox-Gastaut syndrome(ESTEL trial) - Linda Dalic (Australia)
• The analogy between structural networks obtained from diffusion weighted imaging and effective networks derived from single pulse electrical stimulation in people with epilepsy - B. Jelsma (Netherlands)

Genetics

Co-chairs: Sarah Weckhuysen (Belgium)

• Functional analysis of SCN1A non-canonical splice-site variants reveals high rate of false-positive causative variants - Peter Sparber (Russian Federation
• In vitro human model of focal cortical dysplasia demonstrates early junctional instability in the neuroepithelium and network hyperexcitability - Iscia Lopes-Cendes (Brazil)
• Impact of genetic testing on therapeutic decision making in childhood-onset epilepsies - a study of a tertiary referral centre - Allan Bayat (Denmark)
• Delineation of the epileptic and neurodevelopmental phenotype associated with germline variants of the RORB gene - Zeynep Gokce-Samar (France)
• The neonatal presentation of BRAT1-encephalopathy - Evelina Carapancea (Belgium)

Psychiatry & Neuropsychology

Co-chairs: Andriy Dubenko (Ukraine)

• Discrepancy between subjective and objective memory change after epilepsy surgery and relation with quality of life - Florian Johannes Muecke (Germany)
• Machine learning applications to differentiate comorbid functional seizures and epilepsy from pure functional seizures - Ali A. Asadi-Pooya (Iran, Islamic Republic of)
• Ictal SPECT in psychogenic non epileptic seizures (PNES). Identification of functional brain networks involved in PNES. - Maria Centeno (Spain)
• Temporal trend of increasingly later age at onset of mesial temporal lobe epilepsies between 1997 and 2018 suggests changing etiologies with distinct neuropsychological features. - Christoph Helmstaedter (Germany)
• Lesion extent impacts cognitive functioning in pediatric focal epilepsy - Ilona Yakoub (Switzerland)
• Seizure duration and postictal perfusion in a human seizure model - Julia C. M. Pottkämper (Netherlands)

The 14th European Epilepsy Congress, Geneva, Switzerland, 09/07/2022-13/07/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 34 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. 

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. 

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.  

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. 

If you have any questions, please contact the Congress Secretariat at eec@epilepsycongress.org. 

Instructions for converting EACCME® credits to AMA PRA Category 1 Credit™